As of December 31, 2018, the company had approximately $28.8M of cash and cash equivalents. The company raised approximately $20.5M of net cash proceeds in December 2018. With these funds and its cash on hand, the company estimates that it has between 24-36 months of cash for continuing operations. “Given our strong cash position, which was bolstered by our recent fundraising, we are very well positioned to continue with our ongoing confirmatory clinical trial and other development activities,” stated Dr. Charles Ryan, Neurotrope’s CEO. “With 24 to 36 months of cash available for research and development and operations, we do not anticipate needing to raise additional capital anytime in the near future.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.